IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
The trial is a phase III, multicenter, open-labeled randomized trial comparing the
association 5-fluorouracil (5-FU), folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX)
versus oxaliplatin, folinic acid, 5-FU (mFOLFOX 6) chemotherapy protocols in patients with
high-risk stage III colon cancer in the adjuvant setting.